NCT01209039View on ClinicalTrials.gov

A Repeat Dose Positron Emission Tomography Study With GSK1144814

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 1, 2009

Primary Completion Date

October 25, 2009

Study Completion Date

October 25, 2009

Conditions
Schizophrenia
Interventions
DRUG

GSK1144814

Multiple daily doses of GSK1144814 for 28 days

DRUG

GSK1144814

Multiple daily doses of GSK1144814 for 14 days

DRUG

GSK1144814

Multiple daily doses of GSK1144814 for 7 days (or until steady state is reached)

Trial Locations (2)

HA1 3UJ

GSK Investigational Site, Harrow

W12 ONN

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY